Vektor Medical Unveils Cutting-Edge, AI-based Arrhythmia Research at HRX 2023

Vektor’s Leadership Team Named HRX AbstracX Innovators, Presenting Groundbreaking Studies on CT Scar Imaging and Wall Thickness Analysis at HRX 2023

SEATTLE--(BUSINESS WIRE)--Vektor Medical, developers of the only FDA-cleared technology to accurately map arrhythmias using just 12-lead ECG data, is set to showcase two innovative research breakthroughs at HRX 2023, the Heart Rhythm Society’s digital health innovation conference. The company’s Chief Technology Officer, Chris Villongco, Ph.D., and Vice President of Technology, Christian Márton, Ph.D., were selected as AbstracX Innovators and will unveil groundbreaking research on CT Scar Imaging and Wall Thickness Analysis, illuminating the broad potential of non-invasive arrhythmia analysis and Vektor Medical’s vMap technology.

In the first study titled ‘AI-Based Wall Thickness Analysis to Predict Arrhythmogenic Myocardial Substrate,’ Márton introduces an end-to-end automated pipeline for segmenting left ventricles, calculating wall thickness, and rendering these insights on a 3D mesh.

In the second study, ‘A Multi-Modal Workflow for Integrating AI-Based CT Scar Imaging and Computational ECG Mapping Targets for Ventricular Tachycardia Ablation,’ Villongco discusses a novel approach to combining AI-based CT wall thinning analysis with vMap’s non-invasive arrhythmia localization analysis. In turn, these insights enabled a fused patient-specific 3D anatomical model with predicted substrate and source targets to guide a completely non-invasive ventricular tachycardia ablation strategy.

These abstracts underscore the transformative potential of non-invasive analysis and vMap to revolutionize arrhythmia care.

HRX AbstracX Sessions:

• Session II – Friday, September 22 AI-Based Wall Thickness Analysis to Predict Arrhythmogenic Myocardial Substrate, presented by Christian Márton, Ph.D., VP of Technology
• Session III – Saturday, September 23 A Multi-Modal Workflow for Integrating AI-Based CT Scar Imaging and Computational ECG Mapping Targets for Ventricular Tachycardia Ablation, presented by Chris Villongco, Ph.D., CTO

Vektor Medical’s AI-based CT Analysis is not currently commercially available.

About vMap^®

vMap is the sole FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway.

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com